Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
- PMID: 7504740
- PMCID: PMC236300
- DOI: 10.1128/JVI.68.1.400-410.1994
Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
Abstract
The immune response to viral glycoproteins is often directed against conformation- and/or glycosylation-dependent structures; synthetic peptides and bacterially expressed proteins are inadequate probes for the mapping of such epitopes. This report describes a retroviral vector system that presents such native epitopes on chimeric glycoproteins in which protein fragments of interest are fused to the C terminus of the N-terminal domain of the murine leukemia virus surface protein, gp70. The system was used to express two disulfide-bonded domains from gp120, the surface protein of human immunodeficiency virus type 1 (HIV-1), that include potent neutralization epitopes. The resulting fusion glycoproteins were synthesized at high levels and were efficiently transported and secreted. A fusion protein containing the HXB2 V1/V2 domain was recognized by an HIVIIIB-infected patient serum as well as by 17 of 36 HIV-1 seropositive hemophiliac, homosexual male and intravenous drug user patient sera. Many of these HIV+ human sera reacted with V1/V2 domains from several HIV-1 clones expressed in fusion glycoproteins, indicating the presence of cross-reactive antibodies against epitopes in the V1/V2 domain. Recognition of gp(1-263):V1/V2HXB2 by the HIVIIIB-infected human patient serum was largely blocked by synthetic peptides matching V1 but not V2 sequences, while recognition of this construct by a broadly cross-reactive hemophiliac patient serum was not blocked by individual V1 or V2 peptides or by mixtures of these peptides. A construct containing the V3 domain of the IIIB strain of HIV-1, gp(1-263):V3HXB2, was recognized by sera from a human and a chimpanzee that had been infected by HIVIIIB but not by sera from hemophiliac patients who had been infected with HIV-1 of MN-like V3 serotype. The reactive sera had significantly higher titers when assayed against gp(1-263):V3HXB2 than when assayed against matching V3 peptides. Immunoprecipitation of this fusion glycoprotein by the human serum was only partially blocked by V3 peptide, indicating that this infected individual produced antibodies against epitopes in V3 that were expressed on the fusion glycoprotein but not by synthetic peptides. These data demonstrated that the chimeric glycoproteins described here effectively present native epitopes present in the V1/V2 and V3 domains of gp120 and provide efficient methods for detection of antibodies directed against native epitopes in these regions and for characterization of such epitopes.
Similar articles
-
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.J Virol. 1993 Oct;67(10):6136-51. doi: 10.1128/JVI.67.10.6136-6151.1993. J Virol. 1993. PMID: 7690418 Free PMC article.
-
Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.Vaccine. 1998 Nov;16(19):1803-11. doi: 10.1016/s0264-410x(98)00182-0. Vaccine. 1998. PMID: 9795384
-
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.J Virol. 1993 Feb;67(2):863-75. doi: 10.1128/JVI.67.2.863-875.1993. J Virol. 1993. PMID: 7678308 Free PMC article.
-
[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Enferm Infecc Microbiol Clin. 2009. PMID: 19409660 Review. Spanish.
-
Pathogenesis of human immunodeficiency virus infection.Microbiol Rev. 1993 Mar;57(1):183-289. doi: 10.1128/mr.57.1.183-289.1993. Microbiol Rev. 1993. PMID: 8464405 Free PMC article. Review.
Cited by
-
A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Mol Immunol. 2015 Aug;66(2):364-74. doi: 10.1016/j.molimm.2015.04.011. Epub 2015 May 18. Mol Immunol. 2015. PMID: 25965315 Free PMC article.
-
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005. J Virol. 2005. PMID: 15890935 Free PMC article.
-
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017. PLoS One. 2017. PMID: 28678869 Free PMC article.
-
Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.J Virol. 2006 Jun;80(12):6093-105. doi: 10.1128/JVI.00205-06. J Virol. 2006. PMID: 16731948 Free PMC article.
-
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.J Virol. 2004 Mar;78(5):2394-404. doi: 10.1128/jvi.78.5.2394-2404.2004. J Virol. 2004. PMID: 14963135 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources